Those Who Invested in Imugene (ASX:IMU) Five Years Ago Are up 361%

Yahoo FinanceApr 25 07:23

Broker Says This ASX Biotech Stock Could Almost Double in Value

If you're the type of investor that likes high risk-high reward investments, then read on.

The Motley FoolApr 23 13:56

Imugene Signs Deal to Sell Manufacturing Facility For $6 Million

Imugene (ASX:IMU) signed a deal to sell its manufacturing facility in North Carolina to contract development and manufacturing organization Kincell for a total of $6 million, according to a Tuesday fi

MT NewswiresApr 16 14:21

Imugene Commences Enrolment for Cholangiocarcinoma Expansion Study

Immuno-oncology company Imugene (ASX:IMU) said it has opened enrolment for its expansion study in patients with bile tract cancer or cholangiocarcinoma, according to a Monday filing with the Australia

MT NewswiresApr 15 11:40

Press Release: Imugene's Oncolytic Virotherapy VAXINIA and B Cell Immunotherapy HER-Vaxx Featured at the AACR Annual Meeting 2024

Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024 -- Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA

Dow JonesApr 10 00:00

Imugene Shines at AACR With Promising Cancer Therapy Results From VAXINIA and HER-Vaxx

|Clinical stage immuno-oncology company Imugene Ltd (ASX:IMU, OTC:IUGNF) is showcasing its leading therapies, VAXINIA and HER-Vaxx, at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego from April 5-10.

Investing.com Apr 8 08:29